Volume | 179,634 |
|
|||||
News | - | ||||||
Day High | 7.66 | Low High |
|||||
Day Low | 7.45 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Voyager Therapeutics Inc | VYGR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
7.65 | 7.45 | 7.66 | 7.65 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,064 | 179,634 | $ 7.56 | $ 1,357,168 | - | 6.06 - 14.3398 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:04:32 | 1 | $ 7.4602 | USD |
Voyager Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
405.63M | 54.30M | - | 250.01M | 132.33M | 2.44 | 3.07 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Voyager Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VYGR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 8.04 | 8.04 | 7.2831 | 7.61 | 602,454 | -0.57 | -7.09% |
1 Month | 10.01 | 10.66 | 7.2831 | 8.87 | 603,002 | -2.54 | -25.37% |
3 Months | 7.43 | 10.66 | 7.08 | 8.87 | 665,853 | 0.04 | 0.54% |
6 Months | 6.81 | 11.72 | 6.06 | 8.73 | 640,152 | 0.66 | 9.69% |
1 Year | 7.96 | 14.3398 | 6.06 | 9.48 | 555,188 | -0.49 | -6.16% |
3 Years | 5.265 | 14.3398 | 2.46 | 5.74 | 893,450 | 2.21 | 41.88% |
5 Years | 20.77 | 28.79 | 2.46 | 7.36 | 682,953 | -13.30 | -64.03% |
Voyager Therapeutics Description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies. |